Sign in Subscribe

Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval

Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.

Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Credit: Kyverna Therapeutics
Already have an account? Sign in.